News | Hypertension | September 25, 2015

Study Reveals Medisafe Medication Management Platform Significantly Lowers Blood Pressure

Mobile application promotes better adherence to blood pressure medication, resulting in lowered risk profiles for stroke and other cardiovascular disease

Medisafe, medication management, mHealth platform, blood pressure study, hypertension, adherence

September 25, 2015 — Medisafe, an mHealth platform for medication management, announced the results of its blood pressure study, which showed app users with stage 1 or stage 2 hypertension decreased their systolic blood pressure by 17.7 and 25.3 mmHg, respectively, within 30 days. As the sole biomarker to measure hypertension and with a direct connection to clinical outcomes, blood pressure served as a surrogate for measuring medication adherence in this study.

An estimated 78 million adults in the United States have hypertension – defined by systolic levels above 140 mmHg and diastolic levels above 90 mmHg. This figure is projected to rise to 111 million in 2030, due in part to low rates of medication adherence, as only 51 percent of Americans treated for hypertension are adherent to the long-term therapy prescribed by their doctors.

Medisafe's study examined three risk profiles:

  • Prehypertension (BP 120 to 139 mmHg systolic);
  • Hypertension stage 1 (BP 140 to 160 mmHg systolic); and
  • Hypertension stage 2 (BP above 160 mmHg systolic).

To be included in the study and assigned to a risk profile, users needed at least two readings within a risk profile. These readings were then averaged to provide a baseline. The same logic and calculation was applied for the final week of readings. Medisafe limited the analysis to users reporting readings via their "connected devices" – WiFi- or Bluetooth-enabled blood pressure cuffs automatically transmitting levels to Medisafe – to eliminate the potential for self-reporting bias.

Medisafe framed its research around three leading clinical reference points:

  • According to the American Heart Association, reducing average population systolic blood pressure by 12 to 13 mmHg could reduce incidence of stroke by 37 percent, coronary heart disease by 21 percent and cardiovascular disease mortality by 25 percent;
  • An annual National Institutes of Health (NIH) Report suggests that decreases in systolic blood pressure of 5 mmHg would result in an estimated 14 percent overall reduction in mortality due to stroke, a 9 percent reduction in mortality due to CHD and a 7 percent decrease in all-cause mortality; and
  • The just-published, NIH-funded SPRINT study revealed that even more aggressive treatment targeting 120 mmHg systolic – as opposed to 140 mmHg – led to a 30 percent lower risk of adverse cardiovascular events and 25 percent lower risk of death.

The Medisafe study results found:  

  • 100 percent of stage 2 users reduced their systolic blood pressure. The mean result was a 25.3 mmHg improvement in 30 days;
  • 86 percent of stage 2 users reduced their risk category (i.e., moved to hypertension stage 1 of 140 to 160, or below);
  • 66 percent of stage 1 users reduced their systolic blood pressure. The mean result was a 17.7 mmHg improvement in 30 days;
  • 56 percent of stage 1 users reduced their risk category (i.e., moved to prehypertension systolic of 120 to 139, or below);
  • Against a hypothesis of greater than 5 mmHg decrease in systolic, users in both stages showed high statistical significance with p-values below .001;
  • Users in both stages sustained lower levels, suggesting persisted adherence, for at least an additional 40 days, after which time insufficient data were available; and
  • 23 percent of prehypertension and 9 percent of stage 1 users reduced their systolic blood pressure into the normal range below 120 mmHg.

Study results are consistent with Medisafe's previously announced findings that its users are 86 percent adherent versus the World Health Organization’s (WHO) estimate of 50 percent for the nation as a whole.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Clarius Wireless Ultrasound Scanners Now Available With Advanced Features
News | Ultrasound Imaging| August 09, 2017
Clarius Mobile Health has released advanced features and options for its wireless handheld ultrasound scanner for...
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init